Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

BACKGROUND

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M^pro) inhibitor with potent pan–human-coronavirus activity in vitro.

Matéria original

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

Abstract

BACKGROUND

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment